Journal
CURRENT OPINION IN ONCOLOGY
Volume 31, Issue 2, Pages 54-64Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0000000000000505
Keywords
allograft rejection; checkpoint inhibitors; hepatocellular carcinoma; ipilimumab; kidney transplant; liver transplant; melanoma; nivolumab; organ transplant recipients; pembrolizumab
Categories
Funding
- Department of Medical Oncology, Radiotherapy of the Jules Bordet Institute, Brussels, Belgium
- Department of Medical Oncology and Dermatology of the Erasmus Hospital, Brussels
Ask authors/readers for more resources
Purpose of review Checkpoint inhibitors (CPIs) provide impressive response rates among immunocompetent patients with various solid tumors. So far, organ transplant recipients have been excluded from clinical studies due to the putative risk of allograft rejection however 48 cases of liver and renal transplant patients treated with CPI were already described in literature. Recent findings Here we discuss 19 cases of liver and 29 cases of renal transplant patients who received CPI for advanced cancer. Disease control rate [ stable disease, complete response (CR) and partial response (PR) together] was 35% (21% for liver and 45% for kidney transplant patients). Graft rejection was seen in 37% of liver and 45% and kidney transplant patients. Significantly, our analysis shows that an ` ideal' response occurs in 21% of all patients (antitumor response accompanied with durable graft tolerance). Summary We believe that transplant patients can be treated with CPI in a controlled setting and for well informed patients. To obtain a durable antitumor immune response while avoiding rejection, to be able to adjust immunosuppression and to have the opportunity to develop biomarkers for tumor response and transplant rejection, these patients should be treated according to a clinical care path or a prospective clinical trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available